{"id":750702,"date":"2023-04-25T07:05:33","date_gmt":"2023-04-25T11:05:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/"},"modified":"2023-04-25T07:05:33","modified_gmt":"2023-04-25T11:05:33","slug":"autolus-therapeutics-to-host-virtual-capital-markets-day","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/","title":{"rendered":"Autolus Therapeutics to Host Virtual Capital Markets Day"},"content":{"rendered":"
\n

LONDON, April 25, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics\u00a0plc<\/a>\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a virtual Capital Markets Day on Thursday, April 27, 2023.<\/p>\n

Dr Christian Itin, Chief Executive Officer, together with members of the Autolus management team, will host a live webcast and Q&A session to discuss the clinical and commercial opportunity for Autolus\u2019s lead CAR T program, obe-cel, in development for the treatment of adult patients with Acute Lymphoblastic Leukemia (ALL).<\/p>\n

During the event there will be live presentations from, and a Q&A opportunity with, Key Opinion Leaders, including Dr Lori Muffly, Associate Professor, Blood and Marrow Transplantation and Cellular Therapy at Stanford University, and Dr Clare Roddie, Associate Professor in Haemato\u2013oncology, Cancer Institute at University College London. In addition, Matthew Gitlin, Managing Director of Blue Path Solutions, a consulting firm specializing in health economics, will be presenting. The full agenda is below.<\/p>\n

The event will take place from 10am EDT \/ 3pm BST to 12pm EDT \/ 5pm BST and is open to investors and sell-side analysts. Register for the webcast here<\/a>.<\/p>\n

A recording of the Capital Markets Day and presentation materials will be available on the Company\u2019s website after the event.<\/p>\n

\n Agenda <\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n
\n Presenter<\/strong>\n <\/td>\n\n Presentation <\/strong>\n <\/td>\n<\/tr>\n
\n Dr Christian Itin<\/strong>, CEO <\/p>\n<\/td>\nWelcome and opening remarks<\/td>\n<\/tr>\n
\n Dr Lori Muffly<\/strong>
\n
Associate Professor, Blood and Marrow Transplantation and Cellular Therapy at Stanford University <\/p>\n<\/td>\n		The treatment landscape for ALL<\/td>\n<\/tr>\n
\n Dr Claire Roddie<\/strong>
\n
Associate Professor in Haemato\u2013oncology Research Department of Haematology, Cancer Institute at University College London <\/p>\n<\/td>\n		FELIX programme update<\/td>\n<\/tr>\n
\n Matthew Gitlin<\/strong>, Managing Director
BluePath Solutions <\/p>\n<\/td>\n		Broader market overview and economics<\/td>\n<\/tr>\n
\n Chris Vann<\/strong>, COO<\/p>\n<\/td>\nCommercial roadmap for obe-cel<\/td>\n<\/tr>\n
\n Dr Christian Itin<\/strong>, CEO<\/p>\n<\/td>\nModerated Q&A and final remarks<\/td>\n<\/tr>\n<\/table>\n

\n
\n About Autolus Therapeutics plc<\/strong>
\n
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding the continued development of Autolus\u2019 obe-cel program including timing of and expectations regarding planned readouts as well as expectations that the final data set will be confirmatory of the data from the interim analysis; expectations the trial will result in sufficient data to support the utility of obe-cel across the full range of disease burden; the status of clinical trials (including, without limitation, expectations regarding the data that is being presented, the expected timing of data releases and development, as well as completion of clinical trials) and development timelines for the Company\u2019s product candidates; the planned submission of a Biologics License Application for obe-cel by the end of 2023; the expected benefits of the Company\u2019s collaborations and partnerships as well as the anticipated receipt of milestone payments; and the sufficiency of the Company\u2019s cash resources and its anticipated cash runway into 2025. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus\u2019 preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing, and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus\u2019 business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus\u2019 actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Autolus’ Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.<\/p>\n

\n Contact: <\/strong>\n <\/p>\n

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com<\/a><\/p>\n

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com<\/u><\/a><\/p>\n

Jessica Hodgson
Consilium Strategic Communications
autolus@consilium-comms.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON, April 25, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics\u00a0plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a virtual Capital Markets Day on Thursday, April 27, 2023. Dr Christian Itin, Chief Executive Officer, together with members of the Autolus management team, will host a live webcast and Q&A session to discuss the clinical and commercial opportunity for Autolus\u2019s lead CAR T program, obe-cel, in development for the treatment of adult patients with Acute Lymphoblastic Leukemia (ALL). During the event there will be live presentations from, and a Q&A opportunity with, Key Opinion Leaders, including Dr Lori Muffly, Associate Professor, Blood and Marrow Transplantation and Cellular Therapy at Stanford University, and Dr Clare Roddie, Associate Professor … <\/p>\n

Continue reading “Autolus Therapeutics to Host Virtual Capital Markets Day”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-750702","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAutolus Therapeutics to Host Virtual Capital Markets Day - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autolus Therapeutics to Host Virtual Capital Markets Day - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON, April 25, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics\u00a0plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a virtual Capital Markets Day on Thursday, April 27, 2023. Dr Christian Itin, Chief Executive Officer, together with members of the Autolus management team, will host a live webcast and Q&A session to discuss the clinical and commercial opportunity for Autolus\u2019s lead CAR T program, obe-cel, in development for the treatment of adult patients with Acute Lymphoblastic Leukemia (ALL). During the event there will be live presentations from, and a Q&A opportunity with, Key Opinion Leaders, including Dr Lori Muffly, Associate Professor, Blood and Marrow Transplantation and Cellular Therapy at Stanford University, and Dr Clare Roddie, Associate Professor … Continue reading "Autolus Therapeutics to Host Virtual Capital Markets Day"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T11:05:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDI5OSM1NTUzNzQzIzIwOTk2MzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Autolus Therapeutics to Host Virtual Capital Markets Day\",\"datePublished\":\"2023-04-25T11:05:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/\"},\"wordCount\":864,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDI5OSM1NTUzNzQzIzIwOTk2MzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/\",\"name\":\"Autolus Therapeutics to Host Virtual Capital Markets Day - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDI5OSM1NTUzNzQzIzIwOTk2MzA=\",\"datePublished\":\"2023-04-25T11:05:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDI5OSM1NTUzNzQzIzIwOTk2MzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDI5OSM1NTUzNzQzIzIwOTk2MzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/autolus-therapeutics-to-host-virtual-capital-markets-day\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autolus Therapeutics to Host Virtual Capital Markets Day\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autolus Therapeutics to Host Virtual Capital Markets Day - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/","og_locale":"en_US","og_type":"article","og_title":"Autolus Therapeutics to Host Virtual Capital Markets Day - Market Newsdesk","og_description":"LONDON, April 25, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics\u00a0plc\u00a0(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, will host a virtual Capital Markets Day on Thursday, April 27, 2023. Dr Christian Itin, Chief Executive Officer, together with members of the Autolus management team, will host a live webcast and Q&A session to discuss the clinical and commercial opportunity for Autolus\u2019s lead CAR T program, obe-cel, in development for the treatment of adult patients with Acute Lymphoblastic Leukemia (ALL). During the event there will be live presentations from, and a Q&A opportunity with, Key Opinion Leaders, including Dr Lori Muffly, Associate Professor, Blood and Marrow Transplantation and Cellular Therapy at Stanford University, and Dr Clare Roddie, Associate Professor … Continue reading \"Autolus Therapeutics to Host Virtual Capital Markets Day\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T11:05:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDI5OSM1NTUzNzQzIzIwOTk2MzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Autolus Therapeutics to Host Virtual Capital Markets Day","datePublished":"2023-04-25T11:05:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/"},"wordCount":864,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDI5OSM1NTUzNzQzIzIwOTk2MzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/","name":"Autolus Therapeutics to Host Virtual Capital Markets Day - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDI5OSM1NTUzNzQzIzIwOTk2MzA=","datePublished":"2023-04-25T11:05:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDI5OSM1NTUzNzQzIzIwOTk2MzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDI5OSM1NTUzNzQzIzIwOTk2MzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/autolus-therapeutics-to-host-virtual-capital-markets-day\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Autolus Therapeutics to Host Virtual Capital Markets Day"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750702","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=750702"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750702\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=750702"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=750702"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=750702"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}